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7SHORT REPORT Open AccessThe matrix metalloproteinase inhibitor RS-130830
attenuates brain injury in experimental
pneumococcal meningitis
Fabian D Liechti1, Fabian Bächtold1, Denis Grandgirard1, David Leppert2 and Stephen L Leib1,3*Abstract
Background: Pneumococcal meningitis (PM) is characterized by high mortality and morbidity including long-term
neurofunctional deficits. Neuropathological correlates of these sequelae are apoptosis in the hippocampal dentate
gyrus and necrosis in the cortex. Matrix metalloproteinases (MMPs) play a critical role in the pathophysiology of PM.
RS-130830 (Ro-1130830, CTS-1027) is a potent partially selective inhibitor of MMPs of a second generation and has
been evaluated in clinical trials as an anti-arthritis drug. It inhibits MMPs involved in acute inflammation but has low
activity against MMP-1 (interstitial collagenase), MMP-7 (matrilysin) and tumour necrosis factor α converting enzyme
(TACE).
Methods: A well-established infant rat model of PM was used where live Streptococcus pneumoniae were injected
intracisternally and antibiotic treatment with ceftriaxone was initiated 18 h post infection (hpi). Treatment with
RS-130830 (75 mg/kg bis in die (bid) i.p., n = 40) was started at 3 hpi while control littermates received the vehicle
(succinylated gelatine, n = 42).
Results: Cortical necrosis was significantly attenuated in animals treated with RS-130830, while the extent of
hippocampal apoptosis was not influenced. At 18 hpi, concentrations of interleukin (IL)-1β and IL-10 were significantly
lower in the cerebrospinal fluid of treated animals compared to controls. RS-130830 significantly reduced weight loss
and leukocyte counts in the cerebrospinal fluid of survivors of PM.
Conclusion: This study identifies MMP inhibition, specifically with RS-130830, as an efficient strategy to attenuate
disease severity and cortical brain injury in PM.
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Pneumococcal meningitis (PM) is an acute disease char-
acterized by high mortality and morbidity rates with per-
sisting neurofunctional sequelae [1]. Neuropathological
correlates of these long-term deficits include apoptosis in
the hippocampus, a region critical for memory acquisition,
and necrotic injury in the cortical areas, which are both
observed in rodent models and human cases [2].
Matrix metalloproteinases (MMPs) have two distinct
biological properties. As convertases, MMPs activate and* Correspondence: stephen.leib@ifik.unibe.ch
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unless otherwise stated.release cytokines and their receptors while as proteinases
they lyse extracellular matrix components. MMPs play
therefore a critical role in different steps of the patho-
physiology of PM, for example in inflammation, blood-
brain barrier disruption and brain damage [3,4]. In the
cerebrospinal fluid (CSF) of patients with bacterial menin-
gitis, MMP-8 and -9 are upregulated and a high MMP-9
concentration is a risk factor to develop neurological se-
quelae [5]. Tumour necrosis factor (TNF) α, interleukin
(IL)-1β and IL-6 are elevated during PM and part of a self-
sustaining circle of inflammation, initiated by the invading
pathogen [2,6,7].
In previous experimental studies of PM, several classes of
MMP inhibitors successfully attenuated cortical injury [8].
RS-130830 (Ro-1130830; CTS-1027; hereafter named RS)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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generation [9,10]. It was originally designed as a strong in-
hibitor of MMP-2, -3, -8, -9, -12, -13 and -14 (>1,000×
more potent compared to MMP-1 and MMP-7), without
inhibiting MMP-1 (interstitial collagenase), since inhibition
of MMP-1 was believed to be associated with musculoskel-
etal side effects. This substrate profile differentiates RS from
previously investigated broad-spectrum MMP inhibitors
[9,11,12]. RS proved to be safe in clinical trials for osteo-
arthritis and to evaluate protective effects on liver fibrosis
in hepatitis C virus patients [13-15]. The aim of the present
study was to evaluate RS for its effect on inflammation and
brain damage in an experimental model of PM.Findings
Infant rat model of pneumococcal meningitis
A well-established infant rat model of PM was used as previ-
ously described [8,16]. All animal studies were approved by
the Animal Care and Experimentation Committee of the
Canton of Bern, Switzerland (license BE 100/11) and
followed the Swiss national guidelines for the performance
of animal experiments. A clinical isolate of Streptococcus
pneumoniae (serotype 3) was prepared as described earlier
[8]. Nursing Wistar rats (Charles River, Sulzfeld, Germany)
weighing 25.6 ± 2.7 g were infected intracisternally on post-
natal day 11 by injection of 10 μl saline containing log10
5.6 ± 5.0 CFU/ml live S. pneumoniae. Intraperitoneal treat-
ment with RS (75 mg/kg bis in die (bid), n = 40) or vehicle
in control littermates (succinylated gelatine; n= 42) was ini-
tiated 3 h post infection (hpi) and repeated 15 min before
injection of ceftriaxone at 18 and 27 hpi. PM was confirmed
by quantitative analysis of bacterial titres in CSF at 18 hpi
(RS: log10 8.2 ± 8.1 CFU/ml, n = 37; control (Ctrl): log10
8.4 ± 8.8 CFU/ml, n= 39; P= 0.52, Mann-Whitney test) [8].
Antibiotic therapy with ceftriaxone (Rocephine®, 2 ×
100 mg/kg bid, intraperitoneally, Roche Pharma, Basel,
Switzerland) was started at 18 hpi.Figure 1 Clinical parameters assessed during acute bacterial meningi
pneumococci and before sacrificing at 42 hpi. Results are presented as per
animals pre-treated with the MMP inhibitor (RS) compared to control anim
observed in fewer (P < 0.05) animals treated with RS compared to littermat
vehicle were similar (hpi, hours post infection; CS, clinical score; *P < 0.05, FStatistical analysis
Statistical analyses were performed by using GraphPad
Prism software (Prism 6 for Windows, GraphPad Software
Inc., San Diego, CA). If not stated otherwise, results are
presented as mean values ± standard deviation. The
D’Agostino and Pearson omnibus normality test was used
to discriminate between parametric and non-parametric
values. To compare data between two groups, an unpaired
Student’s t-test was used for parametric data; otherwise,
the Mann-Whitney test was applied. Mortality rates were
calculated using log rank (Mantel-Cox) test for signifi-
cance based on all infected animals and numbers of ani-
mals sacrificed due to ethical reasons (clinical score ≤2) or
dying spontaneously. Fisher’s exact test was used to com-
pare two outcomes (cortical injury and clinical scores). A
two-tailed P value < 0.05 was considered statistically
significant.
Evaluation of clinical parameters in experimental PM
At infection and at 18, 27 and 42 hpi, all animals were
weighed and scored clinically by an investigator blinded
to the experimental grouping (1 = coma; 2 = does not
stand upright; 3 = stands upright within 30 s; 4 =min-
imal ambulatory activity, stands upright in less than 5 s;
5 = normal). Animals meeting ethical criteria for experi-
mental abortion (clinical score ≤2) were euthanized with
pentobarbital (Esconarkon, Streuli, Uznach, Switzerland,
150 mg/kg, intraperitoneally). During the acute phase of
PM, that is between infection and 42 hpi, weight loss in
animals treated with RS (−3.0 ± 4.1%, n = 31) was signifi-
cantly attenuated compared to littermates (−6.6 ± 3.5%,
n = 28; P < 0.001; Figure 1A). At the peak of disease (27
hpi), the mean clinical score was 3.7 (median 4.0, min. 2.0,
max. 5.0, n = 32) in animals treated with RS and 3.4 in the
control group (median 3.0, min. 2.0, max. 5.0, n = 37;
P = 0.099, Mann-Whitney test). Only 15 of 32 animals
(46.9%) in the RS group reached a clinical score lower
than 4 compared to 27 of 37 animals (73.0%) in thetis. (A) Animals were weighed before intracisternal inoculation with
cent difference from 0 to 42 hpi. Weight loss was attenuated in
als (Ctrl). (B) At 27 hpi, a low-clinical score (CS < 4; severe disease) was
es receiving vehicle. (C) Survival rates of animals treated with RS or
isher’s exact test; ***P < 0.001, Student’s t-test).
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differences between treatment groups were observed at
18 and 42 hpi. Survival rates were similar in animals
treated with RS (29/40, 72.5%) and vehicle-treated litter-
mates (28/42, 66.7%; log-rank test, P = 0.62; Figure 1C).
White blood cells (WBC) were counted in CSF at 18
hpi. Five microlitres of the non-centrifuged CSF was di-
luted 1:20 with 2% acetic acid. Cells were counted after
2 to 3 min in a Neubauer chamber. The difference be-
tween treatment groups did not reach statistical signifi-
cance (RS: 2,044 ± 1,435 cells/μl, n = 13; vehicle: 2,118 ±
1,200 cells/μl, n = 14; P = 0.78; Figure 2A). However, in
animals surviving until the endpoint at 42 hpi, leukocyte
numbers at 18 hpi were significantly lower (P = 0.026) in
RS-treated animals (1,488 ± 488 cells/μl; n = 8) compared
to vehicle-treated animals (3,019 ± 1,218 cells/μl; n = 4).
Inflammatory parameters and collagen content in the CSF
The concentration of selected cytokines involved in the
pathophysiology of PM (TNF, IL-6, IL-1β, IL-10 and inter-
feron γ [6]) was determined in the CSF using microsphere-
based multiplex assays (Luminex Screening Assay, Rat Pre-
mixed Multi-Analyte Kit, R&D Systems, MN, USA). Five
microlitres of CSF supernatant was diluted 1:10 with the
provided assay buffer and measured as published previ-
ously [8]. An overall trend to decreased concentrations in
the RS group compared to the control group was observed,
reaching statistical significance for IL-1β and IL-10 at 18
hpi (Table 1). Peak concentrations for TNF, IL-6 and IL-1β
were observed at 18 hpi, while IL-10 peaked at 27 hpi. At
42 hpi, except for IL-10, all cytokines were under or close
to the detection limit provided by the manufacturer. Sam-
ples below detection were assigned the lowest detected
values observed in the respective assay.
Concentrations of collagen in CSF samples were assessed
as an index of gelatinase/collagenase activity in the CNS asFigure 2 Measurements in samples of cerebrospinal fluid. (A) White b
infection (hours post infection (hpi)). No effect after pre-treatment with the
littermates (control (Ctrl)). Leukocyte counts were reduced after treatment
squares). (B) Total collagen content was quantified at 18 and 27 hpi (optica
were lower in animals treated with RS compared to control littermates, althpresented earlier [8]. A 10-μl CSF supernatant was diluted
to a final volume of 100 μl (final concentration 6 M HCl)
to hydrolyse the collagen to hydroxyproline at 95°C for
20 h. Of the centrifuged supernatant, 17.5 μl was diluted
with 17.5 μl 4 M HCl and used in the Total Collagen Assay
(QuickZyme Biosciences, Leiden, Netherlands). Absorption
was measured at 550 nm. Collagen concentrations in CSF
samples of RS-treated and non-treated animals were equal
at 18 hpi (Ctrl: 684 ± 372 μg/ml, n = 23; RS: 596 ± 219 μg/
ml, n = 20; P = 0.36; Figure 2B) and at 27 hpi (Ctrl: 1,024 ±
301 μg/ml, n = 7; RS: 916 ± 258 μg/ml, n = 11; P = 0.70),
although a trend to lower CSF collagen concentrations in
RS-treated animals was observed.
Histomorphometrical analysis of brain damage
Coronal brain cryosections (45 μm-thick) of animals sacri-
ficed at 42 hpi were stained with cresyl violet. Cortical
damage was assessed systematically as previously pub-
lished [8]. In controls, 11 of 28 animals (39.3%) showed
substantial cortical injury (defined as ≥ 1% of the cortex)
while this ratio was significantly reduced to 10.3% (3 of 29
animals) in littermates treated with RS (Fisher’s exact test,
P = 0.015). In the control group, the mean necrotic area as
percentage of the total cortical volume was 3.8% ± 6.5%
(median 0.0%, min. 0.0%, max. 26.2%; n = 28) while this
area was significantly reduced in the RS group to 0.7% ±
2.8% (median 0.0%, min. 0.0%, max. 14.8%, n = 29; n = 29;
P = 0.012; Figure 3A). The number of WBC in CSF at 18
hpi correlated with the extent of cortical brain injury
(r = 0.74, P = 0.0056, n = 12).
Apoptotic cells (histological features of condensed, frag-
mented dark nuclei; apoptotic bodies) were counted in the
hippocampal dentate gyrus by a person blinded to the ex-
perimental grouping as published previously [8]. In ani-
mals receiving RS, 8.0 ± 8.8 apoptotic cells per visual field
(c/f) were observed (n = 28) compared to 5.9 ± 4.7 c/f inlood cell count in cerebrospinal fluid samples obtained 18 h after
MMP inhibitor (RS) was observed when compared to vehicle treated
with RS in the survivors of the disease (P < 0.05, Mann-Whitney test;
l density at 550 nm [OD550] was used as arbitrary unit). Concentrations
ough this effect did not reach statistical significance (P = ns).
Table 1 CSF cytokine concentrations in infected animals treated with RS or vehicle (Ctrl)
Ctrl, 18 hpi (n = 11) RS, 18 hpi (n = 10) P valueb Ctrl, 27 hpi (n = 8) RS, 27 hpi (n = 7) P valueb
TNF [ng/ml]a 9.8 ± 4.0 (7.4, 5.3, 15.1) 8.9 ± 4.6 (8.0, 2.0, 17.1) 0.93 2.8 ± 2.3 (1.9, 0.9, 8.0) 1.8 ± 1.2 (1.1, 0.9, 4.3) 0.32
IL-6 [ng/ml]a 228 ± 67.4 (241, 127, 349) 173 ± 62.1 (166, 89.8, 299) 0.061 126 ± 96.0 (90.0, 27.1, 268) 120 ± 113 (60.5, 27.5, 317) 0.92
IL-1β [ng/ml]a 6.6 ± 2.7 (6.4, 2.2, 11.1) 3.6 ± 1.6 (3.8, 1.5, 6.3) 0.0079** 5.3 ± 3.8 (4.7, 0.6, 9.7) 3.7 ± 2.5 (3.1, 1.2, 8.0) 0.52
IL-10 [pg/ml]a 237 ± 118 (294, 30.0, 389) 70.2 ± 84.8 (30.0, 30.0, 243) 0.0051** 776 ± 806 (581, 30.0, 2,318) 500 ± 608 (30.0, 30.0, 1,297) 0.33
IFN-γ [ng/ml]a 7.0 ± 4.6 (8.0, 0.38, 13.3) 5.7 ± 5.4 (5.1, 0.38, 16.9) 0.48 8.9 ± 8.8 (7.3, 0.38, 20.0) 7.3 ± 7.0 (5.3, 0.38, 19.6) 0.86
aValues are mean ± standard deviation (median, minimum, maximum); bMann-Whitney U test. hpi, hours post infection; TNF, tumour necrosis factor α; IL,
interleukin; IFN, interferon. **Statistically significant difference (P < 0.01).
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animal of the RS group, apoptosis could not be quantified
due to abundant pyknotic cells.
Discussion
In the present study, RS attenuated cortical injury in infant
rats with PM, which is in line with previous observations
using broad-spectrum MMP inhibitors in PM [8,16-19]. RS
combines high-oral availability and long half-time with an
optimized substrate profile to target MMPs known to be
upregulated in acute inflammation, while sparing MMP-1
and -7, and TNF converting enzyme (TACE), which sets it
apart from other broad-spectrum MMP inhibitors and
gives it a better clinical perspective [11,12,20]. These find-
ings are limited in the present study to a pre-treatment
regimen; however, an impact of the MMP inhibition, al-
though probably inferior, could reasonably be expected in a
more clinically relevant setting, that is starting RS applica-
tion at 18 hpi. This would be in accordance with results of
previous studies investigating other MMP inhibitors in the
same experimental model [17].
Different from its beneficial effects on cortical injury,
apoptosis in the hippocampal dentate gyrus was not in-
fluenced by RS. Metalloproteinase inhibitors targeting
TACE have been shown in previous studies to attenuate
this form of brain injury [8,17]. For RS, only a weakFigure 3 Brain injury 42 h after infection. (A) Statistically significant atte
inhibitor (RS) compared to littermates receiving the vehicle (control (Ctrl)),
(Mann-Whitney test).inhibition of TNF release has been reported with μM
concentrations while the inhibiting concentrations (IC50)
for most MMPs are × 1,000 lower (Roche, data on file,
[9]). Therefore, metalloproteinase inhibitors with select-
ive activity against TACE and MMPs upregulated in PM
may be desirable.
MMP inhibitors prevent blood-brain barrier breakdown
and reduce inflammatory parameters [21], witnessed in
the present study by reduced CSF concentration of IL-1β
and IL-10. We observed reduced leukocyte counts in CSF
samples of surviving animals treated with RS. This finding
may be related to attenuated cytokine release, that is IL-1β
[6]. Attenuation of leukocyte recruitment prevents inflam-
matory processes, including release and activation of
MMPs eventually leading to cortical injury [21,22]. This is
the first observation showing a reduction of CSF WBC in
animals treated with a MMP inhibitor [21], although the
effect was exclusively detected in survivors and the num-
ber of samples available for this analysis was small due to
the limited availability of CSF obtained by puncture in in-
fant rats.
In the present study, hydroxyproline concentrations in
the CSF were analysed as an index of CNS collagenase ac-
tivity. Earlier studies also used gel zymography to determine
CSF concentrations of MMP-9/-2; however, the interpret-
ation of these results in the context of pharmacologicalnuation of cortical necrosis was seen in animals treated with the MMP
while no effect was observed on hippocampal apoptosis (B). *P < 0.05
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strate of MMP-1 [24], which may explain the weak effect of
RS, which is inactive against MMP-1, on CSF collagen con-
centrations in the present study. The strong effect of RS on
weight loss during acute PM, together with the mild effect
on clinical score and survival, indicate relevant beneficial
systemic effects of MMP inhibition in the present study.
This proof-of-concept study in experimental PM demon-
strates a beneficial effect of a partially selective second-
generation MMP inhibitor that specifically targets MMPs
upregulated in PM in attenuation of cortical brain injury.
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